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a b s t r a c t
We previously demonstrated that, in ex vivo cultures, IFNα downregulates the expression of MHC class
II (MHCII) genes in human non-professional APCs associated with pancreatic islets. IFNα has an opposing
effect on MHCII expression in professional APCs. In this study, we found that the mechanism responsible for
the IFNα-mediated MHCII’s downregulation in human MHCII-positive non-professional antigen presenting
human non-hematopoietic cell lines is the result of the negative feedback system that regulates cytokine
signal transduction, which eventually inhibits promoters III and IV of CIITA gene. Because the CIITA-PIV
isoform is mostly responsible for the constitutive expression of MHCII genes in non-professional APCs, we
pursued and achieved the speciﬁc knockdown of CIITA-PIV mRNA in our in vitro system, obtaining a partial
silencing of MHCII molecules similar to that obtained by IFNα. We believe that our results offer a new
understanding of the potential signiﬁcance of CIITA-PIV as a therapeutic target for interventional strategies
that can manage autoimmune disease and allograft rejection with little interference on the function of
professional APCs of the immune system.
c© 2012 Elsevier B.V.
1. Introduction
The functioning of the immune response in infection, transplan-
tation, cancer and autoimmunity is strictly dependent on the level of
expression ofMHCmolecules on the surface of APCs [1]. Any degree of
alterations in expression levels of MHC may inﬂuence various events
downstream of TcR engagement [2,3]. On the basis of their potential
for antigen presentation to T cells, APCs are frequently classiﬁed into
two major categories: professional or non-professional. Professional
APCs have been identiﬁed as cells of hematopoietic origin specialized
in the priming of naive T cells. These cells, including dendritic cells
(DCs), B lymphocytes, and cells of themonocyte/macrophage lineage,
can induce both primary and memory immune responses because of
their constitutive expression of MHC class II (MHCII) molecules and
potent costimulatory molecules. Non-professional APCs have been
identiﬁed as non-bone marrow-derived cells that do not express a
complete range of costimulatory molecules. This deﬁnition applies
to cell types that do not express basal levels of MHCII molecules but
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can be induced to express MHCII molecules in response to IFNγ [4],
as well as to cell types that constitutively express MHCII molecules,
such as thymic epithelial cells [5] and endothelial cells in various
organs [6–8]. Spurious expression of MHCII molecules on non-bone
marrow-derived cells has also been described in tumor cells from
several neoplastic tissues, including glioma and melanoma [9–11].
Finally, the rejection of transplanted organs strictly depends on the
MHCII expression in endothelial and epithelial cells in the transplant
and in the host tissues [12].
MHCII expression is mainly regulated at the level of transcription
by CIITA [4,13], a non-DNA-binding factor that exhibits a cell-type-
speciﬁc, cytokine-inducible anddifferentiation-stage-speciﬁc expres-
sion proﬁle [14]. In humans, four different CIITA transcription prod-
ucts have been identiﬁed, each of which is generated by one inde-
pendent promoter (CIITA-PI, -PII, -PIII, and -PIV) and is active in an
overlapping subset of cell types [15]. CIITA-PIV is generally regarded
as being responsible for IFNγ-inducible expression of CIITA [16,17],
but it has also been described as being constitutively active in many
non-hematopoietic cells [1,6,8,10,18]. In several instances, the silenc-
ing of CIITA-PIVpromoter aswell as its transitory inhibitionhavebeen
held responsible for failure of IFNγ to induceMHCII transcription and
downregulation of basalMHCII expression [19–26].Moreover, a study
on the effects of CIITA-PIV knockout in transgenicmice demonstrated
that the selective deletion of CIITA-PIV does not seem to dramatically
affect MHCII expression in professional APCs while has a signiﬁcant
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effect on MHCII expression in other APCs [27].
Interferon α (IFNα) is a type I IFN with an important role in the
pathogenesis of several autoimmune diseases [28] and cancer im-
munotherapy [29]. In many cell types, type I IFNs block the induction
of MHCII expression by IFNγ [30]. We recently demonstrated that
the treatment with IFNα of human pancreatic islets ex vivo down-
regulates the CIITA-PIV-drivenMHCII constitutive expression in non-
professional APCs associated with islets [6]. In our system, the effect
of IFNα-treatment onMHCIImoleculeswas in contrastwith the effect
observed in professional APCs, where this cytokine upregulates the
expression of MHCII genes. Other examples of discordance of IFNα-
responsiveness in non-professional (melanoma cells) vs. professional
APCs (immune cells) are described in human and mouse systems
[31–33]. Apparently, similar to what happens with IFNγ, the biologi-
cal effect of IFNα on MHCII expression is primarily mediated via the
activation of the JAK/STAT pathway and the subsequent regulation of
CIITA [30,34] by modulation of the promoter IV of this gene [6,35].
The aim of our study is to identify how the molecular system
associated with the inhibitory function of IFNα on MHCII regulation
in non-professional APCs is different from the system that mediates
IFNα-induction of MHCII molecules in cells from the immune system
(i.e., professional APCs). We believe that an understanding of these
contrastingmechanismscanhelp indeveloping therapeutic strategies
based on the tissue-speciﬁc regulation of MHCII gene expression in
autoimmunity and transplantation.
The results presented in this paper provide experimental evi-
dence supporting a simple mechanism that can account for the IFNα-
mediated downregulation of MHCII in those non-professional APCs
where the expression of these genes is mostly due to the constitutive
activation of CIITA-PIV. We believe that this mechanism is due to the
activation of the general negative feedback regulatory circuit of IFNα
in the context of a constitutive weak expression of the target gene
(CIITA-PIII and CIITA-PIV). On the basis of these results we formed
the idea that it might be possible to mimic the IFNα-mediated down-
regulation of MHCII on these cells without the other (frequently un-
wanted) effects of this cytokine. To this purpose, we tested the effec-
tiveness of using theRNA interference technology to selectively knock
down the CIITA-PIV-driven expression of MHCII in non-professional
APCs by speciﬁcally targeting CIITA-PIV mRNA.
2. Materials and methods
2.1. Reagents and cell lines
TheMe10538 andM14 cell lines were both established from spec-
imens obtained from primary tumors of melanoma patients [36,37].
The SKMEL-23 cell linewasderived fromametastatic lesionof human
melanoma [38]. The U87 cell line was derived from human malig-
nant gliomas (ATCC HTB-14) [39]. All cell lines were cultured in RPMI
Medium 1640 with 10% FCS (GIBCO) and 1% penicillin/streptomycin
(Sigma). Recombinant human interferon gamma (IFNγ) was pur-
chased from Peprotech, and recombinant human interferon alpha 2 b
(IFNα) was purchased from PBL Biomedical Laboratories. Viability of
cells after different treatmentswasmeasured throughﬂowcytometry
with 7-AAD and annexin V-FITC staining (BD Biosciences).
2.2. Flow cytometry analysis
Determination of cell surface expression of MHC class I (MHCI)
and MHCII molecules was carried out by cytoﬂuorimetric analysis
using the FACS ARIA cell-sorting system and DIVA software (BD
Biosciences). Direct immunoﬂuorescence was executed using FITC
mouse anti-human HLA-DR, -DQ and -ABC antibodies, along with the
appropriate FITC mouse IgG isotype controls, all purchased from BD
Biosciences. Staining, washing and analysis were performed as per
the manufacturer’s recommendations.
2.3. Measurement of speciﬁc transcripts by quantitative RT-PCR
Total RNA from cells was isolated using the RNeasy Mini Kit from
QIAGEN. All Reverse Transcription reactions were performed using
the QuantiTect RT Kit (QIAGEN). The accumulation of speciﬁc tran-
scripts wasmeasured by real-time PCR using the DNA Engine Opticon
Real-TimePCRDetectionSystem(BIORAD). TheqPCRassayswereper-
formed using the quantity of cDNA obtained by reverse transcribing
10ng of total RNA. The QuantiTect SYBR Green PCR Kit (QIAGEN) was
used to perform all the reactions in the presence of 0.2μM primers
in a total volume of 25μl. All primers used for qRT-PCR were syn-
thesized by PRIMM, and their sequence and annealing temperature
are presented in Table 1. Quantitative RT-PCR (qRT-PCR) reagent con-
trols (reagents without any template or with 10ng of not-reverse-
transcribed RNA) were included in all the assays. Each assay was run
in triplicate and the mean copy number from the three samples was
usedas the result of the single assay. Eachassaywas independently re-
peated at least three times and themean copy number from the three
assays was showed as the result of the experiment ± the standard
error of the mean (SEM). The relative amount of speciﬁc transcripts
was calculated by the comparative cycle thresholdmethod presented
by Livak and Schmittgen [40]. To correct for sample-to-sample vari-
ations in qRT-PCR efﬁciency and errors in sample quantitation, the
level of GAPDH transcript was measured to normalize speciﬁc RNA
levels. External standards were used to establish standard PCR curves
for quantifying copies of transcripts that required an absolute, com-
parative quantitation. Fold-changes in expression were determined
by dividing the normalized quantity of the gene of interest from IFNα-
treated or IFNγ-treated cells by the normalized quantity of the gene
of interest from untreated cells.
2.4. Western blot analysis
Total levels of STAT1, STAT2, P-STAT1, and P-STAT2 molecules
were measured by immunoblot in protein extracts from IFN-treated
and untreated cells. Antibodies speciﬁc for STAT1 (C-terminus), P-
STAT1 (pY701), STAT2, P-STAT2 (pY690), were purchased from BD
Biosciences, while the anti-mouse IgG (Fc speciﬁc)-peroxidase sec-
ondary antibody and the monoclonal anti-alpha-tubulin were from
Sigma-Aldrich. Lysates were prepared from cells plated at 5 ×
105 cells /well in 6-well plates with 2ml of medium. Adherent cells
were removed by brief treatment with trypsin and EDTA (Sigma-
Aldrich) and then combined with non-adherent cells from the same
culture and washed in cold PBS prior to being resuspended in 100μl
of RIPA buffer (10mM Tris–HCl, pH 7.6, 150mMNaCl, 1% NP40). Pro-
tease inhibitor cocktail tablets from Roche were added at 1× con-
centration immediately prior to sample preparation. After 15min
of incubation at 4 ◦C with agitation, samples were centrifuged for
1h at 4 ◦C and 12,500 rpm, and the recovered supernatant was di-
vided into aliquots and stored at −80 ◦C until it was subjected to
polyacrylamide gel electrophoresis. Protein concentrations were de-
termined using a Bio-Rad protein assay (Bio-Rad Inc.) with bovine
serum albumin standards, following the manufacturer’s recommen-
dations. Equal amounts of solubilized proteins (30μg) were diluted
in Laemmli sample buffer and subjected to electrophoresis on 12.5%
acrylamide/bis gels. Proteins were then transferred onto PVDFmem-
branes (Immobilon-P from Millipore) using an electroblotting sys-
tem from Biometra. Membranes were prepared for immunoblotting
by washing in TTBS (10mM Tris–glycine, pH 8.0, 0.15M NaCl, with
0.05% (w/v) Tween-20). Membranes were then blocked in TTBS plus
5% (w/v) non-fat dry milk for 1h, followed by three 5min washes in
TTBS.Membraneswere probed for speciﬁc proteins by 1h incubations
with the speciﬁc antibodies at the dilution suggested by the manu-
facturers. Themembranes were then washed three times in TTBS and
developedwith the recommendeddilution of the secondary antibody.
After 1h, the membranes were washed in TTBS, and the proteins on
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Table 1
Primers for quantitative PCR used in the study






GAPDH G-F AACGGATTTGGTCGTATTGGGC 60 216
G-R TCGCTCCTGGAAGATGGTGATG
HLA-DRA DRA-F GGACAAAGCCAACCTGGAAA 60 120
DRA-R AGGACGTTGGGCTCTCTCAG
HLA-DQA1*01a A1 CGGTGGCCTGAGTTCAGCAA 63 158
A-R GGAGACTTGGAAAACACTGTGACC
HLA-DQA1*03a A3 CTCTGTTCCGCAGATTTAGAAGA 60 151
A-R GGAGACTTGGAAAACACTGTGACC
CIITA C2TA-F CCGACACAGACACCATCAAC 58 222
C2TA-R CTTTTCTGCCCAACTTCTGC
CIITA-PIII P3-F CCTGGCTCCACGCCCTG 55 230
P-R GAACTGGTCGCAGTTGATG
CIITA-PIV P4-F GAGCTGGCGGGAGGGAG 55 244
P-R GAACTGGTCGCAGTTGATG
IRF1 IRF1-F CCTGATACCTTCTCTGATGGACTCA 60 182
IRF1-R CTGTCCGGCACAACTTCCAC
IRF2 IRF2-F GTCTACCGAATGCTGCCCCT 60 276
IRF2-R AATGTCTGGCGGATTGGTGA
SOCS1 SOCS1-F GCAGCTGCACGGCTCCT 60 195
SOCS1-R GGAGACTGCATTGTCGGCTG
SOCS3 SOCS3-F GCGAAGGCTCCTTTGTGGAC 60 250
SOCS3-R GGGAAACTTGCTGTGGGTGA
SMD3-R GGCGAACTCACACAGCTCCA
a HLA-DQA1- allele speciﬁc primers and internal standards were used in our experiments to measure copy number of DQA1-speciﬁc cDNA.
The quantity of DQA1 transcript accumulated in each sample is the results the sum of copy numbers obtained using allele-speciﬁc primers.
HLA-DQA1*01-speciﬁc couple of primers has been used for samples derived from Me10538 (DQA1*01/*03), M14 (DQA1*01/*03), U87
(DQA1*01/*01). HLA-DQA1*03-speciﬁc couple of primers has been used for samples derived from Me10538 and M14.
the nitrocellulose membrane were detected using the ECL Plus de-
tection system (Healthcare/Amersham Biosciences), according to the
manufacturer’s protocol. Each membrane used for the immunoblot
with the P-STAT-speciﬁc antibody was stripped once and reprobed
with the antibody for the corresponding STAT protein. The stripping
consisted of a single incubation of 20min at 60 ◦C with agitation in
the stripping solution (2% SDS, 62.5mM Tris–HCl, pH 6.7, 100mM β-
mercaptoethanol), followed by six 2min washes at RT in TTBS. Mem-
branes were exposed to Fuji X-Ray Films (FUJIFILMMedical Systems).
Enhanced chemiluminescent images of immunoblots were analyzed
by scanning densitometry. Multiple exposures of each blot were used
to obtain grayscale images of each chemiluminescent band and den-
sitometric analysis was achieved by digital image analysis with NIH
ImageJ 1.41 software ( rsb.info.nih.gov/ij/download)using thedefault
settings for the background correction (rolling ball radius 50).
2.5. RNA interference-mediated gene silencing
The transfection of small interfering RNA (siRNA) for gene silenc-
ing was performed using HiPerFect Transfection Reagent (QIAGEN),
as described in the Reagent Handbook. The siRNAs used in this study
were all purchased from QIAGEN. Speciﬁcally, while those directed
against the humanCIITA andHLA-DRA (Hs CIITA 2HP, Hs CIITA 3HP,
Hs HLA-DRA 2 HP, and Hs HLA-DRA 3 HP) were chosen from the list
of predesigned siRNAs, the two siRNAs directed against CIITA-PIV
(CtPIV-a and CtPIV-b) were custom-designed dXdY-overhang siR-
NAs, respectively, targeting the CCAGAGCTGGCGGGAGGGAGA and
CAGCGGTAGGTGCAGCTCACA target DNA sequences. The AllStars
Negative Control siRNA from QIAGEN was used as a negative con-
trol siRNA. The siRNA molecules selected for the experiments were
those showing the highest and most speciﬁc interference potential
against the intended targets (data not shown). The conditions for
the experiments were chosen after we identiﬁed which siRNAs had
the greatest efﬁciency of uptake with the lowest toxicity for the cell
lines included in the study (data not shown). Transfection efﬁciency
was monitored with Cy5-labeled negative control siRNA from QIA-
GEN. The toxicity of the different siRNAs at various concentrations
was measured through ﬂow cytometry with 7-AAD and annexin V-
FITC staining (BD Biosciences). Based on the results of these tests,
we selected one transfection protocol to be used with all cell lines.
Brieﬂy, cells were plated at 3×105 cells/well in 6-well plates and in-
cubated overnight before transfection. A ﬁnal concentration of 50nM
was used for the transfections of all siRNAs (including negative con-
trols). Cells were collected by trypsinization at various times after the
transfection for both ﬂow cytometry analysis and RNA isolation.
2.6. Statistics
The statistical signiﬁcance of differences among results between
IFNα-treated or IFNγ-treated and untreated cells were evaluated by
the Student’s t test (Prism, GraphPad Software). p Values were deter-
mined using the one-tailed t test.
3. Results
3.1. Treatment with IFNα reduces the cell surface expression of MHCII
molecules in human melanoma and glioma cell lines by downregulating
CIITA-PIII and CIITA-PIV
Because treatment with IFNα downregulates constitutive MHCII
expression in non-professional APCs associatedwith pancreatic islets
[6] in an ex vivo system, we investigated whether IFNα regulation of
the expression of MHCII molecules in human non-professional APCs
also diverges from that of professional human APCs using an in vitro
cell culture system. We selected cell lines representing bona ﬁde
non-professional APCs constitutively expressing MHCII molecules.
Because constitutive expression (i.e., IFNγ-independent) of MHCII
genes has been described in melanoma [41] and glioma cell lines
[42] and because both non-bone marrow derived cell types possess
the MHCII-mediated ability to present antigens to CD4+ T lympho-
cytes [43,44], we chose four already well-characterized cell lines that
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Fig. 1. Quantitative analysis of the expression of MHCII molecules after IFNα-treatment of human tumor cell lines. (A) Cytoﬂuorometric analysis of SK MEL-23, Me10538, M14,
and U87 cells after 48h with either no IFNα or 250U/ml of IFNα. Solid histograms represent isotype control mAb background ﬂuorescence for each speciﬁc mAb investigated; open
histograms represent speciﬁc ﬂuorescence from cells stained with antibodies speciﬁc for MHCI (HLA-A,B,C), HLA-DRA, or HLA-DQ (as indicated next to the relative analysis). The
x-axis of each histogram represents speciﬁc ﬂuorescence on a ﬁve-decade logarithmic scale, and the y-axis represents the number of events. Mean ﬂuorescence intensity (MFI)
values are indicated next to the relative analysis. Data presented are from one representative experiment in a series of at least three. (B), (C), and (D) Quantiﬁcation by RT-PCR in
Me10538, M14, and U87 of HLA-DRA- (B) and HLADQA1-speciﬁc (C) mRNA after treatment for 24 and 48h with either no IFNα or 250U/ml of IFNα, and of CIITA-speciﬁc mRNA (D)
after treatment for 16, 24 and 48h with either no IFNα or 250U/ml of IFNα. The results are expressed in copy number as the mean ± SEM of three independent experiments. In
the absence of IFNα, the copy number of all transcripts did not vary signiﬁcantly over the time tested.
could be used for these experiments: three melanoma cell lines (SK
MEL-23, Me10538 and M14) and one glioma cell line (U-87). All of
themshoweda strong IFNγ-dependentupregulationofMHCII expres-
sion (data not shown). To begin, we established the baseline level of
MHCII expression in our cultures of SK MEL-23, Me10538, M14 and
U-87 cells (see Fig. 1, no IFNα data). Flow cytometry analysis of SK
MEL-23 conﬁrmed the lack of expression of MHCII on the cell surface,
matching the absence of HLA-DRA and HLA-DQA1 speciﬁc mRNA, as
tested by quantitative RT-PCR qRT-PCR assay. Unlike SKMEL-23 cells,
the other twomelanoma cell linesMe10538 andM14, and the glioma
cells U87 showed a signiﬁcant level of HLA-DR and -DQ antigens, both
at the protein and at the RNA level.
For IFNα stimulation, cells were cultured with or without IFNα
(250U/ml) for 48h. Because the ability of IFNα to upregulate the ex-
pression ofMHCImolecules inmelanoma cell lines is well established
[45], the HLA-A,B,C immunophenotype was speciﬁcally measured as
a positive control of the effects of this cytokine on gene expression
in the cells used in the study. As shown in Fig. 1A, 48h of incubation
of each of the four cell lines with IFNα resulted in the expected sig-
niﬁcant increase in the density of MHCI molecules on the cell surface
measured asMFI ( p< 0.01). On average, IFNα-treatedMHCII-positive
tumor cells showed a 1.5–2 fold increase of HLA-A,B,C molecules on
the cell surface compared tountreated cells. In allMHCII-positive cells
used as models of non-professional APCs, the ﬂow cytometry anal-
ysis showed a consistent signiﬁcant decrease of the level of MHCII
molecules on IFNα-treated cells compared to untreated cells. The
density of HLA-DR and HLA-DQ heterodimers on the surface of IFNα-
treated cells was reduced to 40% and 50%, respectively, of the density
of the correspondingmolecules onuntreated cells ( p<0.05, for both),
as seen in Fig. 1A. Incidentally, at no time did IFNα induce the expres-
sion of either HLA-DR or HLA-DQ on the cell surface of SK MEL-23.
To determine if the reduction in HLA-DR and HLA-DQ molecules
on the surface of the IFNα-treated non-professional APC was due to
diminished amount of the speciﬁc transcripts, we measured the ac-
cumulation of HLA-DRA and HLA-DQA1 in the total RNA from our
set of samples after 24 and 48h of culture either in the absence or
presence of IFNα. Using a qRT-PCR assay with primers speciﬁc for
the selected genes (Table 1), we observed a notable IFNα-induced
decrease in the accumulation of HLA-DRA and HLA-DQA1 transcripts
that was already signiﬁcant ( p < 0.05) at 24h and much more re-
markable at 48h (Fig. 1 B and C). Taken together, our data conﬁrm
that IFNα stimulation induces the downregulation of MHCII genes in
different types of human non-professional APCs, in contrast with the
observed IFNα-induced upregulation of these genes in professional
APCs [6] and MHCI genes in both professional and non-professional
APCs.
In light of our and other authors’ data on the IFNα-dependent tran-
scriptional regulation of MHCII expression [6,35], we tested whether
IFNα-induced downregulation of these genes observed in human
melanoma and glioma cell lines was a direct consequence of CIITA
downregulation. Using two primers annealing to sequences common
to all the known transcripts generated by the four identiﬁed CIITA
promoters (Table 1), we performed qRT-PCR assays on total RNA from
non-treated cells and from MHCII-positive cells treated for 16, 24 or
48h with IFNα. Our results revealed that treatment with 250U/ml of
IFNα reduced the CIITA-speciﬁc mRNA level in the cells used in our
analysis (Fig. 1 D). This changewas already evident after 16h of treat-
ment and became signiﬁcant after 24 and 48h ( p < 0.05). We next
investigated whether IFNα leads to a selective decrease in transcrip-
tion from speciﬁc CIITA promoters. To this purpose we used primer
pairs that selectively amplify the cDNA derived from CIITA-PI, CIITA-
PIII or CIITA-PIVmRNA isoforms (Table 1) to measure by qRT-PCR the
number of copies of each CIITA isoforms in untreated cells and es-
tablish the pattern of usage of different CIITA promoters in Me10538,
M14 and U-87 (Fig. 2 A). Our results showed that (i) CIITA-PI-speciﬁc
cDNAwas undetectable in all the cell lines tested, (ii) CIITA-PIVmRNA
represented the greater part (70%) of the total CIITA transcripts in Me
10538 and was almost the exclusive isoform in M14 and U-87, and
(iii) CIITA-PIIImRNA represented the 30% of the total CIITA transcripts
inMe 10538 andwas present at very low but reproducibly detectable
levels (< 3% of the total amount of CIITA transcripts per cDNA sample)
in both M14 and U-87.
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Fig. 2. Quantitative analysis of the expression of the CIITA-PI, CIITA-PIII, and CIITA-PIV mRNA isoforms in human tumor cell lines. (A) Characterization of the pattern of usage of
the different CIITA promoters in SK MEL-23, Me10538, M14, and U87 cells. (B) Measurement of CIITA-PIII and CIITA-PIV by qRT-PCR in Me10538 and M14 treated for 15min, 3, 16,
24 and 48h with either no IFNα or 250U/ml of IFNα. The results are expressed in copy number as the mean ± SEM of three independent experiments. In the absence of IFNα, the
copy number of all transcripts did not vary signiﬁcantly over the time tested.
Since it is known that CIITA-PIV as themajor IFNγ responsive pro-
moter for the induction of CIITA expression [15] and that CIITA-PIII is
also regulated by IFNγ in a number of different cell types but with a
level of inducibilityweaker than that of CIITA-PIV [10,46], we thought
that it was important to characterize the kinetics of IFNα-mediated
change in level of both CIITA-PIII and CIITA-PIV transcripts. To this
end, we measured the number of copies of each isoform in the cDNA
samples obtained from Me10538 (as an example of a cell constitu-
tively expressing signiﬁcant levels of both molecules) and M14 (as
an example of a cell expressing almost exclusively CIITA-PIV) after
15min, 3 h, and 16h of treatment with 250U/ml of IFNα. The results
of our qRT-PCR assays (Fig. 2 B) revealed that, shortly after stimulation
(15min), there was a rapid increase in the accumulation of CIITA-PIII
and CIITA-PIV transcripts in both cell lines. This initial activation was
quickly followed by a signiﬁcant decline in the total copy number of
both isoforms of CIITA, already evident at 3 h and more obvious at
16h. After 48h of culture in presence of IFNα, the expression of these
molecules appeared drastically decreased in either Me10538 or M14,
with the copy number of CIITA-PIII and CIITA-PIV molecules repre-
senting in treated cells respectively as little as the 27±5% and the
34±4% of the level in untreated control cells.
Together, these results demonstrate that the IFNα-mediated reg-
ulation of MHCII genes in human tumor cell lines clearly operate
through the targeting of CIITA-PIII and CIITA-PIV by a mechanism in-
ducing an early activation of both promoters prior to their eventual
downregulation.
3.2. Kinetics of CIITA-PIII and CIITA-PIV expression in IFNα treated
nonprofessional APCs suggest negative feedback regulation.
IFNα-induced changes in the expression of CIITA-PIII and CIITA-
PIV showed similar kinetics characterized by a rapid but transient
increase followed by a decrease in expression. This ﬁnding suggested
a working hypothesis where IFNα-mediatedMHCII’s downregulation
in nonprofessional APCs might be the result of the triggering of the
negative feedback system that usually regulates cytokine signal trans-
duction and that, in this instance, eventually reduce the accumulation
of both CIITA isoforms to levels below those constitutive.
In humans, the signaling pathway for the transcriptional induction
of IFN-stimulated genes (ISGs) involve, asmatter of fact, the phospho-
rylation of STAT proteins by JAK kinases associated with the corre-
sponding IFN receptor [28,47] and a negative feedback loop initiated
by cytokine stimulation itself that eventually attenuates the cytokine
signal transduction pathways by activating factors known as suppres-
sors of cytokine signaling (SOCS) [48–50]. To test our hypothesis, we
ﬁrst examined the kinetics of IFNα-dependent STAT1 activation in
our in vitromodel of nonprofessional APCs. To this end, we evaluated
by immunoblotting the level of the phosphorylated form of STAT1 in
extracts from M14 cells cultured either in absence of IFNα or after
15min, 3 hand 6h of treatment with this cytokine. In every blot, each
sample line was analyzed by densitometry and the signals speciﬁc to
P-STAT1 were normalized to α-tubulin as a loading control and then
to the corresponding signal of total STAT1. As shown in Fig. 3A, the
quantity of P-STAT1 appeared almost undetectable in untreated cells,
increased signiﬁcantly after 15min of IFNα stimulation andmarkedly
diminished already after 3h of treatment. Since functionally distinct
biological responses are generated by IFNα and IFNγ through the ac-
tivation ofmostly overlapping signaling pathways, we believed it was
important to compare the kinetics of IFNα-dependent STAT1 activa-
tion to that of IFNγ-dependent STAT1 activation in M14 cells. We
measured the level of the P-STAT1 in extracts from M14 cells cul-
tured either in absence of IFNγ or after 15min and 6h of treatment
with this cytokine. As expected, also in this instance blots densito-
metry revealed a rapid and strong increase of PSTAT1 accumulation
after 15min of stimulation with IFNγ (Fig. 3 B). However, our analy-
sis showed that IFNγ-dependent STAT1 activation in M14 was much
more sustained than the one directed by IFNα, given that after 6h
of stimulation there was only the 50–60% reduction in quantity of
PSTAT1 compared with the amount measured at 15min.
We wondered whether the kinetics of P-STAT1 activation by IFNα
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Fig. 3. Kinetics of STAT1 activation after treatment of human tumor cell lineswith IFNα
and IFNγ. (A) A representative Western blot of protein extracts from M14 cultivated
in the presence or absence of 250U/ml of IFNα for the indicated periods. Illustration
is derived from high resolution scanning of ﬁlms exposed for 30min. Only control
samples extracted from cells after 6h of culture in the absence of IFNα are included
in the picture because there was no signiﬁcant difference (p > 0.5) in the intensity
of chemiluminescent bands between samples after 15min, 3 h, or 6 h of culture. (B) A
representative Western blot of protein extracts from M14 cultivated in the presence
or absence of 250U/ml of IFNγ for the indicated periods. Illustration is derived from
high resolution scanning of ﬁlms exposed for 30min. Only control samples extracted
from cells after 6 h of culture in absence of IFNγ are included in the picture because
therewas no signiﬁcant difference (p> 0.5) in the intensity of chemiluminescent bands
between samples after 15min or 6h of culture.
in MHCII-positive human tumor cells was consistent with our hy-
pothesis that the IFNα-initiated negative feedback loop is responsible
for the reduction of expression of MHCII molecules on these cells’
surface.
We examined the kinetics of expression of factors that drive IFN-
induced P-STAT1 activation as well as its attenuation. We compared
the effects of treatment with either IFNγ or IFNα on the expression
of interferon regulatory factors 1 (IRF1) and 2 (IRF2) (because of their
role in CIITA-PIV promoter activation [34,51]) and on suppressors of
cytokine signaling 1 (SOCS1) and 3 (SOCS3) (because of their role in
repressing IFNγ-dependent CIITA-PIV transcription [50,52]). We per-
formed qRT-PCR assays using speciﬁc primer pairs (see Table 1) on
total RNA isolated fromMe10538, M14 and U-87 cells collected after
24hof culture in absence of IFN and inpresence of either IFNγor IFNα.
This interval of time was chosen to ﬁrst detect any durable activation
of these genes. In agreement with similar measurements performed
in other systems [53], our results (showed in Fig. 4) indicated upreg-
ulation of IRF1 and IRF2 by both IFNs at the concentrations tested.
Notably, IFNα relative to IFNγ induced signiﬁcantly lower ( p < 0.05)
accumulation of both IRF transcripts at 24h in all cell lines tested.
Measurements of the level of SOCS3 transcripts in IFNα-treated cells
relative to IFNγ-treated cells revealed that IFNα induced a signiﬁ-
cantly lower ( p < 0.05) increase of SOCS3 expression in Me10538,
M14 and U87. Finally, the measurement of SOCS1 transcript accu-
mulation, which exhibited a very low basal constitutive expression
in untreated cells, demonstrated a strong upregulation after 24h of
treatment with IFNγ in treated vs. untreated cells and a signiﬁcantly
stronger ( p < 0.05) upregulation after 24h of treatment with IFNα.
To obtain further information on the kinetics of IRF1 and SOCS1
activation in our system,we analyzedbyqRT-PCR the accumulation of
IRF1 and SOCS1 transcripts in M14 cells treated with IFNα for various
time periods (15min, 3 h, 24h, and 48h) and from untreated cells. As
illustrated in Fig. 5, our results showed no appreciable change in the
accumulation of IRF1 transcript in M14 after either 15min or 3h of
culture in presence of IFNα in comparison with untreated cells. How-
ever, a modest increase of IRF transcript is evident in IFNα-treated
cells after 24h, becoming a little more substantial after 48h of stimu-
lation. In contrast with the slow and weak IFNα-driven upregulation
of IRF1 gene, IFNα-driven upregulation of SOCS1 in M14 was robust
within 15min, peaking at 24h of treatment and still active after 48h.
In conclusion, we showed evidence that quantitative differences
in the expression of SOCS1 and IRF1 are underlying the kinetics of a
Fig. 4. Comparison of the expression of the IRF1, IRF2, SOCS1 and SOCS3 genes fol-
lowing treatment of human tumor cell lines with either IFNα or IFNγ. Measurement
of IRF1-, IRF2-, SOCS1-, and SOCS3-speciﬁc mRNA by qRT-PCR in Me10538, M14, and
U87 after treatment for 24h with either 250U/ml of IFNα or 250U/ml of IFNγ. The
results are expressed as themean ± SEM of fold change of the copy number of the IFN-
treated sample relative to the untreated control in three independent experiments. The
method of Student was used to evaluate the statistical signiﬁcance of the differences
between means of IFNγ- or IFNα-treated cell lines. The asterisks (*) indicate a p-value
less than 0.05 using a two-tailed t test.
Fig. 5. Kinetics of IRF1 and SOCS1 activation after IFNα-treatment of human tumor
cell lines. Measurement of IRF1- and SOCS1-speciﬁc mRNA by qRT-PCR in M14 treated
for 15min, 3, 24 and 48h with 250U/ml of IFNα. The results are expressed as the mean
± SEM of fold change of the copy number of the IFN-treated sample relative to the
untreated control in three independent experiments.
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Fig. 6. Quantitative analysis of the expression of MHCII molecules after siRNA-
mediated speciﬁc knockdown of the CIITA-PIV isoform. Cytoﬂuorometric analysis of
Me10538,M14 and U87 cells transiently transfectedwith siRNAs speciﬁc for HLA-DRA,
CIITA, CIITA-PIV, and a negative control siRNA. The density of HLA-DR and HLA-DQ
molecules on the cell surface was measured as ﬂuorescence from cells stained with
speciﬁc antibodies and was expressed as MFI. The results are plotted as the mean ±
SEM of fold change of MFI value relative to sham-transfected cells as a control in three
independent experiments. The method of Student was used to evaluate the statisti-
cal signiﬁcance of the differences between mean fold change of the MFI values. The
asterisks (*) indicate a p-value less than 0.05 using a two-tailed t test.
weak and transient activation of IFNα-dependent STAT1 activation as
well as of CIITA-PII and CIITA–PIV activation.
3.3. MHCII downregulation can be achieved through the selective
silencing of the CIITA-PIV isoform by RNA interference
The unique effects of IFNα on CIITA-PIV expression observed in
these studies suggested that targeting the expression of this isoform
innon-professional APCsmight be aneffectivemeansofmanipulation
ofMHCII expressionwithout critically affecting professional APCs.We
therefore tested the feasibility of utilizing CIITA-PIV speciﬁc RNA in-
terference to downregulate MHCII expression. The effects of the gene
silencing mediated by the speciﬁc interference with HLA-DRA, CIITA,
andCIITA-PIV transcripts on the cell surface expressionofHLA-DRand
HLA-DQ molecules in Me10538, M14 and U87 cells are presented in
Fig. 6. In summary, determination of cell surface expression of MHCII
molecules was performed by direct immunoﬂuorescence using anti-
HLA-DR and -DQ Abs in all cells 72h after transfection with 50nM
of the various siRNAs described in Section 2 (Material and methods).
In all cell lines transfected with the control siRNA, the expression of
either HLA-DR or HLA-DQ on the cell surface was not signiﬁcantly
modiﬁed. Transfection with siRNAs directed against the HLA-DRA se-
quence (indicated as HLA-DRA 2 and HLA-DRA 3 in Fig. 6) were used
as positive controls of speciﬁcity. These siRNAs signiﬁcantly reduced
cell surface expression of HLA-DR in all cell lines tested, without sig-
niﬁcantly affecting the expression of HLA-DQ.
Transfection with two different siRNAs (indicated as CIITA 2 and
CIITA 3 in Fig. 6) each targeting all known human CIITA isoforms sig-
niﬁcantly reduced the surface expression of both HLA-DR and -DQ in
all the MHCII-positive tumor cell lines. Finally, a similar efﬁciency of
knockdown of both the MHCII molecules was achieved by the trans-
fection of two different siRNAs speciﬁcally directed against CIITA-PIV
(indicated as CtPIV-a and CtPIV-b in Fig. 6). To conﬁrm our data on the
MHCII cell-surface expression, wemeasured the amount of HLA-DRA,
HLA-DQA1, CIITA, CIITA-PIV, andCIITA-PIII transcripts in the total RNA
from our set of samples both 16 and 48h after transfection with the
different siRNAs used in our study (including the control siRNA) as
well as in the sham-transfected samples (data not shown). Using an
RT-PCR assay with primers speciﬁc for the selected genes, we con-
ﬁrmed that RNA interference with both HLA-DRA 2 and HLA-DRA 3
siRNAs exclusively affected the accumulation of DRA-speciﬁc RNA;
silencing with the CIITA 2 and CIITA 3 siRNAs was effective on the
accumulation of HLA-DRA-, HLA-DQA1- and all CIITA-speciﬁc RNA;
and, ﬁnally, CtPIV-a and CtPIV-b siRNAs caused, in all instances, the
reduction of the amount of transcripts from both HLA-DRA and HLA-
DQA1 genes aswell as the speciﬁc decline of only the CIITA-PIVmRNA
isoform.
We conclude that by speciﬁcally knocking CIITA-PIV mRNA down
in an in vitro model of non-professional APCs we achieved a level of
MHCII gene downregulation reminiscent of that obtained by the IFNα
treatment.
4. Discussion
Several studies show that treating melanoma patients with IFNα
results in prolonged disease free survival, although the mechanism
of this cytokine remains speculative [54]. Besides its effects on the
host immune cells and its antiangiogenic properties, the antitumor
action of IFNα treatment depends on the direct antiproliferative and
proapoptotic characteristics of IFNα on the cancer cells [33]. Interest-
ingly,MHCII-positivemelanomacells that behave asnon-professional
APCs exhibit a different response to IFNα-induced Jak-STAT signaling
compared to immune cells (i.e., professional APCs) [33]. This fact, cou-
pled with our data indicating the opposing effect of IFNα on MHCII
expression in non-professional vs. professional APCs [6], suggested
that a further deﬁnition of the mechanism responsible for the IFNα-
mediated downregulation of MHCII expression in non-professional
APCs was needed.
The role IFNs as modulators of MHCII gene expression has been
studied in a variety of systems. It is well established that IFNγ induc-
tion of MHCII gene expression operates at the transcriptional level by
upregulating the expression of the CIITA gene. Induction is accom-
plished mostly through the activation of CIITA-IV promoter [4,55],
but also by way of less well characterized mechanisms of activation
of CIITA-PI and CIITA-PIII promoters [46,56–58]. Studies with STAT2
knockout mice have demonstrated that IFNα modulates MHCII ex-
pression differently in different cell types through the CIITA-PIV pro-
moter [35,59]. We have previously described that IFNα downregu-
lates the PIV-driven expression of CIITA in human non-professional
APCs associated with pancreatic islets cultured ex vivo [6]. The op-
posite, upregulatory effect on MHCII expression that we observed
in professional APCs was mostly due to IFNα-mediated persistent
activation of CIITA-PIII and CIITA-PI isoforms, respectively, in B lym-
phoblastoma cell lines and DCs, along with the moderate activation
of CIITA-PIV in both cell types. Indeed, MHCII-mediated antigen pre-
sentation by professional APCs is not affected in CIITA-PIV knockout
mice [27].
CIITA-PIII and PIV promoters are constitutively active in some
melanoma and glioma cells [9,10,42]. The ﬁndings of the study we
describe here reveal that in MHCII-positive non-hematopoietic cells,
which act as non-professional APCs, IFNα inhibits promoters PIII and
PIV of CIITA by amechanism inducing an early activation of both pro-
moters prior to their eventual downregulation. The decrease in the
expression of CIITA-PIII and CIITA-PIV, in turn induces downregula-
tion of MHCII genes, and results in a reduction of the density HLA-DR
and HLA-DQmolecules to 40–50% of the density of the corresponding
molecules on untreated cells. The signiﬁcance of this ﬁnding, as per
the conclusion of Christinck et al. and DiMolfetto et al. [2,3], is based
on the notion that even subtle differences in the level of peptide/MHC
density on APCs can signiﬁcantly inﬂuence the nature of the immune
response.
In all the systems so far characterized, IFNα induces the expression
of ISGs through the activation of STAT1 and STAT2 and the consequent
assembly of two different DNA-binding complexes: IFN-stimulated
gene factor-3 (ISGF-3) and AAF (alpha-activated factors). ISGF-3 com-
plexes interactwith response elements in thepromoters of ISGs called
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ISREs and are composed by P-STAT1, P-STAT2 (responsible for the
unique properties of type I IFNs-dependent STAT1 activation [60])
and, interferon regulatory factor (IRF9) [61]. AAF are P-STAT1 ho-
modimers, indicated asGAF (gamma-activated factors)when they are
produced as signaling molecules for IFNγ, that interact with the GAS
(gamma-interferon-activated) sites in the promoters of ISGs [62,63].
Our central interest in this study was to investigate possible qual-
itative or quantitative differences in the IFNα-induced mechanisms
bringing about CIITA-PIII and CIITA-PIV activation in professional vs.
non-professional APCs. Lymphoblastoid cell lines (LBCL) are often
used as in vitro models of professional APCs. In preliminary stud-
ies, we found that LBCLs were unsuitable as a model because of their
constitutive level of IFNα production [64] and resulting activation
of STAT1 and STAT2 (data not shown). Of note, we did not detect
any IFNα-induced P-STAT2 accumulation at different times of stim-
ulation in all three the MHCII-positive extrahematopoietic cell lines
selected for our study. Because of the absence of STAT2 activation we
concluded that the GAS box present in both CIITA-PIII and CIITA-PIV
promoters [65] must be the DNA cis-element targeted by the IFNα-
mediated MHCII downregulation. Because the GAS box is also the
DNA cis-element targeted by the IFNγ-mediated MHCII upregulation
we proceeded to directly comparing the signaling pathways and the
expression of genes targeting CIITA-PIII and CIITA-PIV after treatment
of these cells with either IFNα or IFNγ. Based on the general pattern
for the course of gene regulation by cytokine activation, we concen-
trated our attention on the duration of signaling and activation of
IFN-triggered signal transduction pathways and their effect on the
expression of CIITA-PIII and CIITA-PIV.
It is well documented that the effect of stimulation with either
type of IFN on the transcription of ISGs relies on the expression and
the extent of the activation of STAT proteins (reviewed in [66]). For
example, IFNγ-mediated induction of CIITA gene expression does not
occur at the expected levelswhen there is only a transient stimulation
with IFNγ, possibly because of the falloff of P-STAT1 levels resulting
in a short-lasting occupancy of CIITA promoter and/or a premature
ending of the IRF1 synthesis [51]. When we measured the accumula-
tion of P-STAT1 in non-professional APCs after treatment with either
IFNγ or IFNα we observed that, while IFNγ directed both the rapid
(i.e., within 15min) and sustained (i.e. after 6h) activation of STAT1,
IFNα-treatment induced a rapid but transient activation of STAT1,
becoming unappreciable after 3h of stimulation.
To investigate the effect of the treatment with either IFNγ or IFNα
on the transcription of known factors that have been shown to be
inducible by both cytokines and are important in the regulation of
CIITA-PIV [34,50-52], we measured the accumulation in Me10538,
M14 and U87 of mRNA speciﬁc for IRF1, IRF2, SOCS1, and SOCS3
after treatment with both cytokines. Our results essentially indicate
two principal differences in the regulation of IRF1, IRF2, SOCS1, and
SOCS3 genes (Fig. 4) that underlie differences in the kinetics of IFNα-
and IFNγ-dependent STAT1 activation (Fig. 3) in our in vitro model
of non-professional APCs: (1) the upregulation of both IRF1 and IRF2
genes, especially IRF1, appeared weaker after 24h of treatment with
IFNα than after 24h of treatment with IFNγ and, (2) SOCS1 appeared
to be the only factor still showing a strong activation (of at least two
order ofmagnitude greater to those of IRF1, IRF2 and SOCS3) after 24h
of IFNα stimulation. Anumberof studies [35,49,50,67,68] showed that
differences in the expression of IRF1 and SOCS1 are associated with
differences in the level and the extent of STAT1 activation and play
an important role in differentiating the biological response to IFNs.
In agreement with the model of Morris et al. [56], we found that
the shorter duration of STAT1 activation detected in non professional
APCs treated with IFNα relative to the duration of STAT1 activation in
the same cells treated with IFNγ is accompanied by a relatively weak
stimulation of IRF1 gene transcription.
SOCS1 inhibits or attenuates cytokine signal transduction path-
ways through binding to JAKs [69] as part of a negative feedback
loop that is initiated by cytokine stimulation itself [48–50]. When
we looked at the kinetics of SOCS1 upregulation after treatment with
IFNα in MHCII-positive non-hematopoietic cells, we found that (1)
in the absence of any IFN stimulation, both the activation of STAT1
and the constitutive expression of SOCS1 were almost undetectable
in all the cell lines and, (2) consistent with the known pathway of
SOCS1 regulation following cytokine-stimulation, there was a rapid
IFNα-dependent upregulation of SOCS1, already evident after 15min
of treatment becoming very strong after 24h of treatment. SOCS1 is
known as an essential physiological regulator of IFN signaling in var-
ious experimental systems and as a potent inhibitor of IFN-induced
immune activities [68]. Studies in vitro have shown that constitutive
overexpression of SOCS1 inhibits IFNα- and IFNγ-mediated activation
of STAT1 aswell as the antiproliferative and antiviral activities of IFNs
[70] and that ectopic expression of SOCS1 inhibits IFNγ-dependent
CIITA-PIV transcription and subsequent MHCII protein expression by
inhibiting the STAT1 phosphorylation and binding to theGAS element
in CIITA-PIV [50]. Studies in vivohave shown that cells frommice lack-
ing SOCS-1 exhibit a prolonged response to IFNγ and a dramatically
increased sensitivity to the toxic effects of IFNγ [71]. We believe that
the IFNα-mediated downregulation of MHCII molecules in our sys-
tem and the block of the IFNγ-induction of MHCII expression driven
by type I IFNs observed in different cell types are indeed two aspects
of the same regulatory mechanism acting through the induction of
SOCS1.
We hypothesized that in nonprofessional APCs, showing consti-
tutive MHCII expression sustained by low levels of the CIITA-PIII
and CIITA-PIV isoform, the IFNα-induced upregulation of CIITA is
quite weak and transient due to the stimulation of the normal IFNα-
initiated negative feedback mechanism that strongly represses these
promoters. As matter of fact, the repression appears to be so strong
that the amount of CIITA-PIII and CIITA-PIV molecules expressed re-
mains below the level of the constitutive expression. Since SOCS1
action is crucial in supporting the IFNα-initiated negative feedback
mechanism, our ﬁnding that IFNα-treatment of Me10538, M14 and
U87 cells strongly induces the accumulation of SOCS1-speciﬁc RNA
solidly support our hypothesis.
In agreement with the hypothesis articulated by other authors
on the expression of MHCII proteins on human endothelial cells and
their role as non-professional APC [8,72–74], we believe the reason
why non-endocrine cells populating human islets express MHCII is to
aid in immune surveillance of the endocrine pancreas. Several studies
have demonstrated that CIITA is a target formodulation by pathogens
that are controlledbyCD4+Tcells [75]. There is evidence thatdifferent
viruses inhibit different steps in the IFNγ signal transduction pathway
leading to induction of CIITA [76], but the effect of pathogen infec-
tion on constitutive transcription of CIITA in professional APCs still
requires further investigation [77]. Our study, while it does not reveal
newmechanisms involved in MHCII downregulation by pathogens is
original in two fundamental aspects: (i) we provide evidence demon-
strating that the action of IFNα may be an intermediate step in the
effect of pathogen infection on MHCII downregulation and, (ii) we
identify constitutive expression of CIITA in non-professional APCs as
a target ofmodulation by pathogens andwedescribe themechanisms
responsible for downregulation.
Moreover, we propose that, in agreement with the conclusions
obtained by studying CIITA-PIV knockout mice [27], the targeting
of this molecule in vivo would result “in a highly selective loss of
MHCII-mediated antigen presentation by nonprofessional APCs.” In
the current study, we proved the feasibility of using RNA interference
technology to successfully and speciﬁcally knock down CIITA-PIV in
melanoma and glioma cell lines, to an extent that is deﬁnitely compa-
rable to that obtained by IFNα treatment and, therefore, biologically
relevant. Indeed, our studymay contribute to the design and develop-
ment of manipulations of CIITA-PIV expression in vivo, resulting in a
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selective reduction of MHCII-mediated antigen presentation by non-
professional APCs, without hindering expression of MHCII molecules
in professional APCs.
We believe that this system may be relevant for studies directed
toward the development of novel therapies of autoimmune diseases
without the unwanted side effects of systemic immunosuppression.
Similar interventions may also be used to treat chronic graft rejec-
tion mediated by direct allorecognition of disparate MHCII antigens
expressed by nonprofessional APCs (e.g. endothelial cells) [12].
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